Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
Abstract:
The present disclosure describes novel PKC-ϵ activators chosen from halogenated esters of unsaturated fatty acids derivatives thereof, including halogenated esters of both polyunsaturated and monunsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.
Information query
Patent Agency Ranking
0/0